Clinical Trial Update: AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine [Phase 2]

View source ↗

Summary

AZD2171 (cediranib) was studied in Neurofibromatosis Type 1–associated neurofibromas, including plexiform neurofibromas and spinal cord neurofibromas; the Phase…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurofibromatosis Type
• Plexiform Neurofibroma
• Spinal Cord Neurofibroma

Drugs mentioned

• AZD2171 (cediranib) (cediranib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Neurofibromatosis Type 1, Plexiform Neurofibroma | Phase 2 | Status: TERMINATED | Results posted: 2013-09-26